Scantox Group, a portfolio company of Impilo, has acquired QPS Austria’s Neuropharmacology Division

QPS Neuro

QPS Neuro, the neuropharmacology division of QPS Austria, is highly experienced and specialized in preclinical central nervous system (CNS) services. QPS Neuro has developed its reputation since 1999 as a high-quality contract research organization (CRO) and a leading specialist in Alzheimer’s, Parkinson’s, ALS, Dementia, Niemann-Pick, Gaucher, Autism, Schizophrenia, Frontotemporal Lobar Degeneration and other neurodegenerative and rare diseases. The company’s reputation within CNS is further enhanced by its strong capabilities in pre-clinical efficacy studies including in vitro molecular and cellular analysis and proprietary in vivo transgenic mouse and rat models with associated analytics offered to a broad portfolio of customers.

The Deal

Scantox Group, together with its majority owner Impilo, has agreed to acquire the neuropharmacology division of QPS Austria ultimately owned by QPS Holdings. This is a transformational acquisition that will expand Scantox’s value chain coverage and reposition its existing drug discovery platform significantly with unique and market-leading CNS research capabilities. QPS Neuro will continue its operations as part of the Scantox group. The combined company will have more than 300 employees across six sites offering discovery models including neuropharmacology research services, regulatory toxicology and chemistry, manufacturing and controls / analytical services.

Our Perspective

James West, Lincoln International Managing Director who led the transaction, commented, “QPS Neuro is a leader in the field of pre-clinical CNS services, a sector and therapy area which has drawn significant investment interest in recent years. It has been a pleasure to work with the Impilo and Scantox teams to combine the businesses, which positions Scantox as a global player for pre-clinical services. Lincoln excels in advising on these situations, involving transformative, cross-border transactions and we all will continue to follow Scantox’s journey.”

QPS Holdings, LLC

QPS is a good laboratory practice (GLP) / good clinical practice compliant CRO delivering discovery, preclinical and clinical drug development services. Founded in 1995 and headquartered in the U.S., QPS has more than 1,110 employees in the U.S, Europe, India and Asia.

Scantox Group

Scantox is the leading Nordic pre-clinical GLP-accredited CRO, focused on pharmacology and regulatory toxicology, headquartered in Denmark with subsidiaries in Sweden and Denmark. Based on decades of experience, Scantox is a trusted partner for product development services within the pharmaceutical, biotechnology and medical devices industries, with a world-known expertise within the Göttingen minipigs. Scantox’s services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards. Founded in 1977, Scantox is today owned by Impilo, the leading Nordic healthcare investment company.

Impilo

Impilo is a Nordic investment company focused on long-term investments in sustainable healthcare companies active in pharmaceuticals, medical technology, healthcare services and other health-related areas. Impilo strives to increase the value of its investments through long-term active ownership. Impilo has a well-diversified portfolio of investments and has raised approximately €1 billion in capital from leading Nordic and international investors since its inception in 2017.

Share: